Effects of tiotropium on lung function in current smokers and never smokers with bronchial asthma - PubMed

Affiliations

• PMID: 27888045
• DOI: 10.1016/j.pupt.2016.11.004

Randomized Controlled Trial

Effects of tiotropium on lung function in current smokers and never smokers with bronchial asthma

Makoto Yoshida et al. Pulm Pharmacol Ther. 2017 Feb.

Abstract

The effects of tiotropium, an inhaled long-acting muscarinic antagonist, on lung function were investigated in current smokers and nonsmokers with asthma treated with inhaled corticosteroids (ICSs) and other asthma controllers: inhaled long-acting β₂ agonists, leukotriene receptor antagonists, and/or theophylline. We conducted a double-blind, placebo-controlled study of an inhaled single dose of tiotropium in 9 asthmatics currently smoking and 9 asthmatics who have never smoked in a crossover manner. Lung function was measured before and 1, 3, and 24 h after inhalation of 18 μg of tiotropium or a placebo. The primary outcome was a change in forced expiratory volume in 1 s (FEV₁) from the baseline, and the secondary outcomes were changes in peak expiratory flow rate (PEFR), V˙₅₀, and V˙₂₅. At baseline, asthmatics with and without a smoking history had a mean FEV₁ of 2590 ml and 2220 ml and were taking a mean dose of ICSs of 1208 and 1000 μg/day, respectively. The increase from the baseline FEV₁ was 169 ml and 105 ml higher at 3 h after tiotropium than after the placebo in current smokers and nonsmokers, respectively. PEFR, V˙₅₀, and V˙₂₅ were also significantly increased after tiotropium as compared with the placebo in both study groups. Changes in FEV₁ and PEFR tended to be greater in asthmatics currently smoking than in subjects who have never smoked, although there were no statistical differences at any time points. Tiotropium resulted in improved lung function and symptoms both in current smoker and nonsmoker asthmatics. These findings suggest that tiotropium will provide a new strategy for the treatment of bronchial asthma.

Keywords: Bronchial asthma; Current smoker; Tiotropium.

Similar articles

• Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.

  Timmer W, Moroni-Zentgraf P, Cornelissen P, Unseld A, Pizzichini E, Buhl R. Timmer W, et al. Respir Med. 2015 Mar;109(3):329-38. doi: 10.1016/j.rmed.2014.12.005. Epub 2014 Dec 27. Respir Med. 2015. PMID: 25661281 Clinical Trial.

• Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials.

  Kerstjens HA, Casale TB, Bleecker ER, Meltzer EO, Pizzichini E, Schmidt O, Engel M, Bour L, Verkleij CB, Moroni-Zentgraf P, Bateman ED. Kerstjens HA, et al. Lancet Respir Med. 2015 May;3(5):367-76. doi: 10.1016/S2213-2600(15)00031-4. Epub 2015 Feb 12. Lancet Respir Med. 2015. PMID: 25682232 Clinical Trial.

• Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.

  Ohta K, Ichinose M, Tohda Y, Engel M, Moroni-Zentgraf P, Kunimitsu S, Sakamoto W, Adachi M. Ohta K, et al. PLoS One. 2015 Apr 20;10(4):e0124109. doi: 10.1371/journal.pone.0124109. eCollection 2015. PLoS One. 2015. PMID: 25894430 Free PMC article. Clinical Trial.

• Efficacy and safety of tiotropium in school-age children with moderate-to-severe symptomatic asthma: A systematic review.

  Rodrigo GJ, Neffen H. Rodrigo GJ, et al. Pediatr Allergy Immunol. 2017 Sep;28(6):573-578. doi: 10.1111/pai.12759. Pediatr Allergy Immunol. 2017. PMID: 28692145 Review.

• Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators.

  Halpin DM, Kaplan AG, Russell RK. Halpin DM, et al. Respir Med. 2017 Jul;128:28-41. doi: 10.1016/j.rmed.2017.04.008. Epub 2017 Apr 18. Respir Med. 2017. PMID: 28610667 Review.

Cited by

• Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan.

  Umeda A, Shimada H, Yamane T, Mochizuki T, Inoue Y, Tsushima K, Miyagawa K, Mochida A, Takeda H, Okada Y, Masaki K, Matsusaka M, Fukunaga K. Umeda A, et al. Front Physiol. 2023 Apr 21;14:1131949. doi: 10.3389/fphys.2023.1131949. eCollection 2023. Front Physiol. 2023. PMID: 37179838 Free PMC article.

• Impact of Air Pollution on Asthma Outcomes.

  Tiotiu AI, Novakova P, Nedeva D, Chong-Neto HJ, Novakova S, Steiropoulos P, Kowal K. Tiotiu AI, et al. Int J Environ Res Public Health. 2020 Aug 27;17(17):6212. doi: 10.3390/ijerph17176212. Int J Environ Res Public Health. 2020. PMID: 32867076 Free PMC article. Review.

• Tiotropium in asthma: back to the future of anticholinergic treatment.

  Bonini M, Scichilone N. Bonini M, et al. Clin Mol Allergy. 2017 Dec 4;15:20. doi: 10.1186/s12948-017-0076-1. eCollection 2017. Clin Mol Allergy. 2017. PMID: 29213218 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information